Update regarding AIM admission of RenalytixAI

EKF Diagnostics Holdings plc (AIM: EKF) announces that, further to the announcement on 31 October confirming that Renalytix AI plc (“RenalytixAI”) had successfully raised £22.25 million in gross proceeds, RenalytixAI will now be admitted to trading on AIM on 6 November 2018. An updated Schedule One announcement is expected to be issued on 2 November 2018.

Participants in the fundraising will be contacted by N+1 Singer, the Company or Link Asset Services to confirm updated settlement instructions.

EKF and N+1 Singer, the Company’s current nominated adviser and broker, have agreed that in order to preserve the independence of its nominated adviser, EKF will appoint a new nominated adviser after the admission of RenalytixAI.  A further announcement will be made in this regard in due course. 

N+1 Singer will continue to act as broker to EKF.